The prediction of human clearance from hepatic microsomal metabolism data

Current Opinion in Drug Discovery and Development

Volumn 4, Issue 1, 2001, Pages 36-44

  Obach, R S ^a  

^a PFIZER INC   (United States)

Author keywords

Hepatic clearance; Hepatocyte; In vitro in vivo correlation; Liver microsomes; Pharmacokinetics

Indexed keywords

2,8 DIMETHYL 3 METHYLENE 1 OXA 8 AZASPIRO[4.5]DECANE; 6 CHLORO 4 CYCLOPROPYL 3,4 DIHYDRO 4 [(2 PYRIDYL)ETHYNYL] 2(1H) QUINAZOLINONE; BOSENTAN; DOLASETRON MESILATE; DONEPEZIL; DRUG; DRUG METABOLIZING ENZYME; EZLOPITANT; FELODIPINE; GESTAGEN; IMIPRAMINE; INDINAVIR; METOPROLOL; MIDAZOLAM; MOFAROTENE; N,N DIETHYL N' (1 ETHYL 6 METHYL 8ALPHA ERGOLINYL)SULFAMIDE; PROPRANOLOL; VERAPAMIL; WARFARIN;

CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG HALF LIFE; DRUG RESEARCH; HUMAN; HUMAN CELL; KIDNEY CLEARANCE; LIVER CLEARANCE; LIVER MICROSOME METABOLISM; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; HUMANS; METABOLIC CLEARANCE RATE; MICROSOMES, LIVER; PHARMACEUTICAL PREPARATIONS; PREDICTIVE VALUE OF TESTS;

EID: 0035147471     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. A physiological approach to hepatic drug clearance
2. Hepatic clearance of drugs. I. Theoretical considerations of a 'well-stirred' model and a 'parallel tube' model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance
3. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance
4. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data
5. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and non-specific binding to microsomes
6. Non-specific binding to microsomes: Impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol
7. Non-specific binding of drugs to human liver microsomes
8. Effects of freezing, thawing, and storing human liver microsomes on cytochrome P450 activity
9. Correlation between in vivo and in vitro hepatoic uptake of metabolic inhibitors of cytochrome P450 in rats
10. Quantitative prediction of metabolic inhibition of midazolam by erythromycin, diltiazem, and verapamil in rats: Implication of concentrative uptake of inhibitors into liver
11. Inhibition of desipramine hydroxylation (cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: Relation to drug interactions in vivo
12. Extrapolating in vitro data on drug metabolism to in vivo pharmacokinetics: Evaluation of the pharmacokinetic interaction between amitriptyline and fluoxetine
13. Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport
14. Integration of in vitro data into allometric scaling to predict hepatic metabolic clearance in man: Application to 10 extensively metabolized drugs
15. The use of human hepatocytes to select compounds based on their expected hepatic extraction ratios in humans
16. Prediction of hepatic metabolic clearance based on interspecies allometric scaling techniques and in vitro-in vivo correlations
17. Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance
18. In vivo pharmacokinetics of felodipine predicted from in vitro studies in rat, dog and man
19. Prediction of in vivo drug disposition from in vitro data based on physiological pharmacokinetics
20. Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data
21. Predicting the hepatic clearance of xenobiotics in humans from in vitro data
22. Predicting the oral bioavailability of 19-nortestosterone progestins in vivo from their metabolic stability in human liver microsomal preparations in vitro
23. Predictability of the in vivo metabolism of verapamil from in vitro data: Contribution of individual metabolic pathways and stereoselective aspects
24. The biotransformation of the ergot derivative CQA 206-291 in human, dog and rat liver slice cultures and prediction of in vivo plasma clearance
25. Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients
26. Bosenten, a new endothelin receptor antagonist: Prediction of the systemic plasma clearance in man from combined in vivo and in vitro data
27. In vivo and in vitro kinetics of mofarotene in mouse, rat, dog and man
28. Species differences in the metabolism of a potent HIV-1 reverse transcriptase inhibitor L-738,372. In vivo and in vitro studies in rats, dogs, monkeys, and human
29. Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor
30. Prediction of species differences (rats, dogs, humans) in the in vivo metabolic clearance of YM796 by the liver from in vitro data
31. Prediction in vivo hepatic metabolic clearance of YM796 from in vitro data by use of human liver microsomes and recombinant P450 isozymes
32. Prediction of the pharmacokinetic parameters of reduced-dolasetron in man using in vitro in vivo and interspecies allometric scaling
33. Correlation of the intrinsic clearance of donepezil (Aricept) between in vivo and in vitro studies in rat, dog and human
34. Comparison of CYP2D6 content and metoprolol oxidation between microsomes isolated from human livers and small intestines
35. Metabolism of ezlopitant, a non-peptidic substance P receptor antagonist, in liver microsomes: Enzyme kinetics, cytochrome P450 isoform identity, and in vitro in vivo correlation
36. Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans
37. Prediction of in vivo non-linear first-pass hepatic metabolism of YM796 from in vitro metabolic data
38. Sigmoidal kinetics of CYP3A substrates: An approach for scaling dextromethorphan metabolism in hepatic microsomes and isolated hepatocytes to predict in vivo clearance in rat
39. In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model
40. Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques
41. Quantitative structure-pharmacokinetic relationships (QSPR) of ß-blockers derived using neural networks
42. Computational approaches for prediction of human in vitro intrinsic clearance